News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Northfield Laboratories Blood Substitute Misses Phase 3 Trial Goals
May 23, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CHICAGO, May 23 (Reuters) - Northfield Laboratories Inc. said on Wednesday that its red blood cell substitute, PolyHeme, failed to meet the primary goals of mortality and safety in a pivotal Phase III study.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
MORE ON THIS TOPIC
Vaccines
Quick on Its Feet: Novavax Adapts to Continued Regulatory Uncertainty
June 20, 2025
·
3 min read
·
Heather McKenzie
Obesity
Scholar Rock Jumps on Weight Loss Data for Zepbound/Repurposed Antibody Combo
June 18, 2025
·
2 min read
·
Dan Samorodnitsky
Approvals
CSL Wins First Approval for Preventive Hereditary Angioedema Drug
June 18, 2025
·
2 min read
·
Tristan Manalac
Parkinson’s disease
Ventyx’s Parkinson’s Pill Shows ‘Promising’ Results in Mid-Stage Study, Paving Path to Other Neuro Diseases
June 17, 2025
·
2 min read
·
Tristan Manalac
